Yesterday, September 10th, 2019, Vingulmork Predictor AS, a company controlled by Erling Sundrehagen, Chief Scientific Officer in Gentian Diagnostics AS (“Gentian”), has sold 311,627 shares at NOK 43 per share in a block trade raising gross proceeds of approximately NOK 13.4 million (the “Transaction”). 

The proceeds will be used to settle a legal dispute between Vingulmork Predictor AS and another party in connection with the building of a conference center in Vestby Kommune. After the Transaction, Erling Sundrehagen and associated companies own 224,083 shares in Gentian. Erling Sundrehagen and associated companies have entered into a lock-up agreement for 6 months with DNB Markets for the remaining shares they hold in Gentian.

Hilja Ibert, Chief Executive Officer of Gentian, has purchased 5,813 shares in the Transaction. After the Transaction, Hilja Ibert and associated companies own 5,813 shares and 139,963 share options in Gentian.

Njaal Kind, Chief Financial Officer of Gentian, has purchased 10,000 shares in the Transaction. After the Transaction, Njaal Kind owns 20,000 shares and 34,991 share options in Gentian.

Tomas Settevik, Chairman of the board of Gentian, has purchased 23,255 shares in the Transaction through his company Mutus AS. After the Transaction, Tomas Settevik and associated companies own 210,465 shares in Gentian.

Henrik Krefting, Board member of Gentian, has purchased 40,000 shares in the Transaction. After the Transaction, Henrik Krefting owns 40,000 shares in Gentian.

P53 Invest AS, represented on the board of Gentian by Susanne Stuffers, has purchased 23,255 shares in the Transaction. After the Transaction, P53 Invest AS owns 133,255 shares in Gentian.

Kari Krogstad, Board member of Gentian, has purchased 2,325 shares in the Transaction. After the Transaction, Kari Krogstad and associated companies own 2,323 shares in Gentian.

Teakay Invest AS, represented on the board of Gentian by Ingrid Teigland Akay, has purchased 2,325 shares in the Transaction. After the Transaction, Teakay Invest AS owns 60,779 shares in Gentian.

Vatne Equity AS, major shareholder in Gentian, and associated companies, has purchased 204,654 shares in the Transaction. After the Transaction, Vatne Equity AS and associated companies owns 2,264,994 shares in Gentian.

DNB Markets acted as manager for the Transaction.


This information is subject to the disclosure requirements set out in section 5-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Njaal Kind
CFO, Gentian Diagnostics AS
E-mail: njaal.kind@gentian.no
Cell Phone: +47 919 06 525